<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01465048</url>
  </required_header>
  <id_info>
    <org_study_id>VAC049</org_study_id>
    <nct_id>NCT01465048</nct_id>
  </id_info>
  <brief_title>Optimisation of Controlled Human Malaria Infection Using Sporozoites Administered by Needle and Syringe</brief_title>
  <official_title>A Pilot Study to Optimise Controlled Human Malaria Infections Using Plasmodium Falciparum Sporozoites Administered by Needle and Syringe</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanaria Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, human pilot study to optimise controlled human malaria infection&#xD;
      (CHMI) administered by Plasmodium falciparum sporozoites (PfSPZ. Volunteers will be&#xD;
      inoculated with PfSPZ Challenge. The route of administration and dose will vary in order to&#xD;
      identify the optimal regimen that achieves the greatest infection rate in volunteers with&#xD;
      Plasmodium falciparum. All volunteers recruited will be healthy adults aged between 18 and 45&#xD;
      years. Safety and infectivity data will be collected for each of the regimens.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Studies involving CHMI are a powerful tool for investigating malaria vaccine and prophylactic&#xD;
      drug efficacy.CHMI has now become established as a key tool to assess the efficacy of novel&#xD;
      malaria vaccines and drugs. As CHMI trials are carried out in a controlled environment, they&#xD;
      allow unprecedented detailed evaluation of parasite growth and immunological responses,&#xD;
      providing essential information for vaccine and drug development.&#xD;
&#xD;
      Out of three currently available methods of performing experimental human malaria infections&#xD;
      (blood stage infection, mosquito bites and sporozoite infection), experimental injection&#xD;
      directly by needle and syringe using aseptic, purified, cryopreserved sporozoites is, in&#xD;
      principle, the most accurate and practical way of dosing sporozoites for challenge studies.&#xD;
      Recently, Sanaria Inc have been able to overcome the technical issues associated with the&#xD;
      production of aseptic, purified, cryopreserved Plasmodium falciparum sporozoites. As a&#xD;
      result, an Investigational New Drug application (IND) was submitted to the U.S. Food and Drug&#xD;
      Administration in February 2009, and a Phase 1 clinical trial with experimental challenge of&#xD;
      volunteers was initiated in April 2009. Another trial sponsored by Sanaria to find the dose&#xD;
      of aseptic, purified, cryopreserved sporozoites that should be used for experimental human&#xD;
      malaria infections is currently ongoing with collaboration with the Radboud University&#xD;
      Nijmegen Medical Center, The Netherlands.&#xD;
&#xD;
      This trial will be the first time aseptic, purified, cryopreserved P. falciparum sporozoites&#xD;
      have been administered intramuscularly to humans.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Infected</measure>
    <time_frame>21 days post administration of PfSPZ Challenge</time_frame>
    <description>To determine the infectivity rates of PfSPZ Challenge administered in various regimens by thick film microscopy and highly sensitive PCR for Plasmodium falciparum DNA.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency, Incidence and Nature of Adverse Events and Serious Adverse Events Arising.</measure>
    <time_frame>Participants will be followed for the duration of the study, an expected average of 3 months</time_frame>
    <description>To assess the safety of PfSPZ Challenge administered in various regimens by analysing actively and passively collected data from clinical review of volunteers and laboratory measurements, including lab reports and adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dynamics of Plasmodium Falciparum Parasite Growth Following PfSPZ Challenge Administered in Various Regimens</measure>
    <time_frame>21 days post administration of PfSPZ Challenge</time_frame>
    <description>To determine the parasite growth dynamics of PfSPZ Challenge administered in various regimens using highly sensitive PCR for Plasmodium falciparum DNA.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Malaria</condition>
  <condition>Plasmodium Falciparum</condition>
  <arm_group>
    <arm_group_label>Plasmodium falciparum sporozoites 2sites</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2,500 sporozoites intradermally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Plasmodium falciparum sporozoites 1 site</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2,500 sporozoites intramuscularly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Plasmodium falciparum sporozoites 1site</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25,000 sporozoites intramuscularly</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Plasmodium falciparum sporozoites 2sites</intervention_name>
    <description>Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, 2,500 sporozoites, 50ulx2, 2 intradermal injection sites</description>
    <arm_group_label>Plasmodium falciparum sporozoites 2sites</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Plasmodium falciparum sporozoites 1 site</intervention_name>
    <description>Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, 2,500 sporozoites, 50ulx2, 2 intramuscular injection sites</description>
    <arm_group_label>Plasmodium falciparum sporozoites 1 site</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Plasmodium falciparum sporozoites 1site</intervention_name>
    <description>Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, 25,000 sporozoites, 50ulx2, 2 intramuscular injection sites</description>
    <arm_group_label>Plasmodium falciparum sporozoites 1site</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women only: Must practice continuous effective contraception for the duration of the&#xD;
             study.&#xD;
&#xD;
          -  Agreement to refrain from blood donation during the course of the study and for at&#xD;
             least 3 years after the end of their involvement in the study.&#xD;
&#xD;
          -  Written informed consent to undergo CHMI.&#xD;
&#xD;
          -  Reachable (24/7) by mobile phone during the whole study period.&#xD;
&#xD;
          -  Willingness to take a curative anti-malaria regimen.&#xD;
&#xD;
          -  For volunteers not living in Oxford: agreement to stay in a hotel room close to the&#xD;
             trial centre during a part of the study (At least Day 6.5 post inoculation until 2&#xD;
             days after treatment commenced).&#xD;
&#xD;
          -  Answer all questions on the informed consent quiz correctly.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of clinical P. falciparum malaria.&#xD;
&#xD;
          -  Travel to a malaria endemic region during the study period or within the preceding six&#xD;
             months with positive P. falciparum serology at screening.&#xD;
&#xD;
          -  Use of systemic antibiotics with known antimalarial activity within 30 days of study&#xD;
             enrolment (e.g. trimethoprim-sulfamethoxazole, doxycycline, tetracycline, clindamycin,&#xD;
             erythromycin, fluoroquinolones and azithromycin)&#xD;
&#xD;
          -  Receipt of an investigational product in the 30 days preceding enrollment, or planned&#xD;
             receipt during the study period.&#xD;
&#xD;
          -  Prior receipt of an investigational malaria vaccine.&#xD;
&#xD;
          -  Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV&#xD;
             infection; asplenia; recurrent, severe infections and chronic (more than 14 days)&#xD;
             immunosuppressant medication within the past 6 months (inhaled and topical steroids&#xD;
             are allowed).&#xD;
&#xD;
          -  Use of immunoglobulins or blood products within 3 months prior to enrollment.&#xD;
&#xD;
          -  History of sickle cell anemia, sickle cell trait, thalassemia or thalassemia trait.&#xD;
&#xD;
          -  Pregnancy, lactation or intention to become pregnant during the study&#xD;
&#xD;
          -  A history of allergic disease or reactions likely to be exacerbated by malaria&#xD;
             infection.&#xD;
&#xD;
          -  Contraindications to the use of all three proposed anti-malarial medications;&#xD;
             Malarone, Riamet and Chloroquine.&#xD;
&#xD;
          -  History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in&#xD;
             situ).&#xD;
&#xD;
          -  History of serious psychiatric condition that may affect participation in the study.&#xD;
&#xD;
          -  Any other serious chronic illness requiring hospital specialist supervision.&#xD;
&#xD;
          -  Suspected or known current alcohol abuse as defined by an alcohol intake of greater&#xD;
             than 42 units every week.&#xD;
&#xD;
          -  Suspected or known injecting drug abuse in the 5 years preceding enrollment.&#xD;
&#xD;
          -  Seropositive for hepatitis B surface antigen (HBsAg).&#xD;
&#xD;
          -  Seropositive for hepatitis C virus (antibodies to HCV).&#xD;
&#xD;
          -  An estimated, ten year risk of fatal cardiovascular disease of ≥5%, as estimated by&#xD;
             the Systematic Coronary Risk Evaluation (SCORE) system.39&#xD;
&#xD;
          -  Positive family history in 1st and 2nd degree relatives &lt; 50 years old for cardiac&#xD;
             disease.&#xD;
&#xD;
          -  Volunteers unable to be closely followed for social, geographic or psychological&#xD;
             reasons.&#xD;
&#xD;
          -  Any clinically significant abnormal finding on biochemistry or haematology blood&#xD;
             tests, urinalysis or clinical examination.&#xD;
&#xD;
          -  Any other significant disease, disorder or finding which may significantly increase&#xD;
             the risk to the volunteer because of participation in the study, affect the ability of&#xD;
             the volunteer to participate in the study or impair interpretation of the study data.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian VS Hill, DPhil FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oxford</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>October 27, 2011</study_first_submitted>
  <study_first_submitted_qc>November 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2011</study_first_posted>
  <results_first_submitted>April 8, 2013</results_first_submitted>
  <results_first_submitted_qc>April 8, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 28, 2013</results_first_posted>
  <last_update_submitted>June 18, 2013</last_update_submitted>
  <last_update_submitted_qc>June 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Malaria</keyword>
  <keyword>Protozoan Infections</keyword>
  <keyword>Parasitic Diseases</keyword>
  <keyword>Malaria Challenge</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Malaria</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PfSPZ Challenge 2,500 ID</title>
        </group>
        <group group_id="P2">
          <title>PfSPZ Challenge 2,500 IM</title>
        </group>
        <group group_id="P3">
          <title>PfSPZ Challenge 25,000 IM</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PfSPZ Challenge 2,500 ID</title>
        </group>
        <group group_id="B2">
          <title>PfSPZ Challenge 2,500 IM</title>
        </group>
        <group group_id="B3">
          <title>PfSPZ Challenge 25,000 IM</title>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Infected</title>
        <description>To determine the infectivity rates of PfSPZ Challenge administered in various regimens by thick film microscopy and highly sensitive PCR for Plasmodium falciparum DNA.</description>
        <time_frame>21 days post administration of PfSPZ Challenge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PfSPZ Challenge 2,500 ID</title>
          </group>
          <group group_id="O2">
            <title>PfSPZ Challenge 2,500 IM</title>
          </group>
          <group group_id="O3">
            <title>PfSPZ Challenge 25,000 IM</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Infected</title>
          <description>To determine the infectivity rates of PfSPZ Challenge administered in various regimens by thick film microscopy and highly sensitive PCR for Plasmodium falciparum DNA.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency, Incidence and Nature of Adverse Events and Serious Adverse Events Arising.</title>
        <description>To assess the safety of PfSPZ Challenge administered in various regimens by analysing actively and passively collected data from clinical review of volunteers and laboratory measurements, including lab reports and adverse events.</description>
        <time_frame>Participants will be followed for the duration of the study, an expected average of 3 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dynamics of Plasmodium Falciparum Parasite Growth Following PfSPZ Challenge Administered in Various Regimens</title>
        <description>To determine the parasite growth dynamics of PfSPZ Challenge administered in various regimens using highly sensitive PCR for Plasmodium falciparum DNA.</description>
        <time_frame>21 days post administration of PfSPZ Challenge</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>07/11/11 to 13/02/12</time_frame>
      <group_list>
        <group group_id="E1">
          <title>PfSPZ Challenge 2,500 ID</title>
        </group>
        <group group_id="E2">
          <title>PfSPZ Challenge 2,500 IM</title>
        </group>
        <group group_id="E3">
          <title>PfSPZ Challenge 25,000 IM</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Malasie</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Gum Bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Susanne Sheehy</name_or_title>
      <organization>University of Oxford</organization>
      <email>susanne.sheehy@balliol.ox.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

